+91-8668442535

Acquired Hemophilia Treatment Market By Type Of Therapeutics (Traditional Therapy, Advanced Therapy) - Growth, Share, Opportunities & Competitive Analysis, 2016 - 2023

According to the National Organization of Rare Disorders (NORD), acquired hemophilia is a rare autoimmune disorder characterized by bleeding in patients with a personal and family history of hemorrhages. The body produces antibodies that attack clotting factors in acquired hemophilia, most often factor VIII. Medical practitioners suggest that acquired hemophilia can potentially cause life-threatening bleeding complications in severe cases and that, in around 50% of cases, there is an identifiable underlying clinical condition; in the other 50%, no cause is known, i.e., idiopathic.

The "Global Acquired Hemophilia Treatment Market-Growth Future Prospects and Competitive Analysis, 2016–2023" offers strategic insights into the overall acquired hemophilia treatment market along with the market size and estimates for 2016 to 2023. The research study includes an in-depth examination of multiple market segments based on the therapeutic type and geographical region. The therapeutic type segment studied for analyzing the overall acquired hemophilia treatment includes two major categories: traditional and advanced therapies. The traditional therapies are further sub-categorized into steroid treatment, cytotoxic treatment, and immunomodulatory treatment. The advanced therapies are further segmented into Desmopressin, Recombinant Activated Factor VII/NovoSeven, Recombinant Activated Factor VIII/Obizur, and Activated Prothrombin Complex Concentrate (aPCC)/FEIBA.

In order to help strategic decision-makers, the report also includes competitive profiling of the leading players in the acquired hemophilia treatment market, attractive investment propositions, and market positioning of key manufacturers. Other in-depth analysis provided in the report includes:

Geographically, the global acquired hemophilia treatment market is studied for the following regional markets:

North America

  • U.S.
  • Canada

Europe

  • U.K.
  • Germany
  • The rest of Europe

Asia-Pacific

  • China
  • Japan
  • Asia Pacific as a whole

Latin America

  • Africa and the Middle East

The market size and forecast for these regional and country-level markets are presented in this study for the period 2013–2023. In addition, market growth rates for the forecast period 2016–2023 are also included in this report, considering 2015 as the base year.

This study also provides quantitative and qualitative information sets and assessment tools to better analyze the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges, and opportunities assists the readers in understanding the ongoing trends in the global acquired hemophilia treatment market. In addition, tools such as key player market positioning and appealing investment propositions provide readers with insights into the competitive landscape of the global acquired hemophilia treatment market. This report concludes with a company profiles section highlighting major information about the key players engaged in the globally acquired hemophilia treatment market. In-depth competitive environment analysis and historical (2013 & 2014) market size data are also provided in the report.

So, the research study gives a complete picture of the global acquired hemophilia treatment market by estimating the market size from 2016 to 2023 and considering the above factors. 

Based on the therapeutic, the acquired hemophilia treatment market is segmented into:

  • Traditional Therapies
  • Steroid Treatment
  • Cytotoxic Treatment
  • Immunomodulatory Treatment
  • Advanced Therapies
  • Desmopressin
  • Recombinant Activated Factor VII [NovoSeven]
  • Recombinant Activated Factor VIII/Obizur
  • Activated Prothrombin Complex Concentrate (aPCC)/FEIBA

According to the National Organization of Rare Disorders (NORD), acquired hemophilia is a rare autoimmune disorder characterized by bleeding that occurs in patients with a personal and family history of hemorrhages. The body produces antibodies that attack clotting factors in acquired hemophilia, most often factor VIII. Treatment strategies that are applied against acquired hemophilia are based on two major objectives. The primary objective is to achieve effective control of bleeding manifestations during acute bleeding episodes. The secondary and ultimate therapeutic objective is eliminating the inhibitor and curing the disease. The acquired hemophilia treatment market on the basis of therapeutics has been segmented into two major categories, such as traditional and advanced therapies. The traditional therapies are further sub-categorized into steroid treatment, cytotoxic treatment, and immunomodulatory treatment. The advanced therapies are further segmented into Desmopressin, Recombinant Activated Factor VII/NovoSeven, Recombinant Activated Factor VIII/Obizur, and Activated Prothrombin Complex Concentrate (aPCC)/FEIBA. The advanced therapies held the largest segment due to the introduction of novel therapies for the treatment of acquired hemophilia. According to a prospective study, FEIBA administration resulted in excellent hemostasis in 100% of patients. However, the market for traditional therapies is expected to grow at a stable rate during the forecast period due to the patent expiration of advanced therapy drugs and the introduction of breakthrough drugs currently in clinical studies.

Frequently asked questions :

The market for Acquired Hemophilia Treatment is expected to reach US$ XX Bn in 2023.

The Acquired Hemophilia Treatment market is expected to see significant CAGR growth over the coming years, at XX%.

The report is forecasted from 2016-2023.

The base year of this report is 2015.

Baxalta, Inc 42, Baxter Healthcare Corporation 43, Bristol-Myers Squibb 44, Genentech, Inc. 45, Novo Nordisk A/S 46 are some of the major players in the global market.

Choose License Type
Trusted By
Godaddy
Published Date:  Jan 2017
Category:  Pharmaceuticals
Report ID:   57894
Report Format:   PDF
Pages:   120
Rating:    4.7 (80)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support